Journal Browser

► Journal Browser

Special Issue "Recent Advances in Immunotherapy for Solid Tumors"

Share This Special Issue

Special Issue Editors

E-Mail Website
Guest Editor

Fresh Wind Biotechnologies, Houston, TX, USA
Interests: immunotherapy; translational research; immuno-oncology;preclinical study;clinical study;immune-monitoring; immune pProfiling; cancer vaccines;adoptive cell therapies

Dr. Yoshimi Arima
E-Mail Website
Guest Editor

Cancer Center, Fujita Health University, Toyoake, Japan
Interests: tumor biology; molecular biology; molecular pathology

Special Issue Information

Dear Colleagues,

The special issue titled "Recent Advances in Immunotherapy for Solid Cancer" presents a comprehensive overview of research highlighting the latest breakthroughs in the immunotherapy for solid tumors. The issue brings together state of art technologies and studies that delve into various aspects of immunotherapy, including novel treatment approaches, combination strategies, biomarkers, and immune-related adverse events. This special issue focus on the remarkable progress made in harnessing the immune system to battle solid cancers. It covers a wide range of topics, including, but are not limited to adoptive cell therapies, immune checkpoint inhibitors, monoclonal antibodies, small molecules, cytokines, cancer vaccines, and oncolytic viruses. Moreover, the issue explores the role of the tumor microenvironment, neoantigens, and immune escape mechanisms in shaping the efficacy of immunotherapeutic interventions.

In addition, the special issue emphasizes the importance of personalized medicine in immunotherapy, with articles focusing on patient-specific approaches such as neoantigen identification, immune profiling, biomarkers, and targeted therapies. The integration of genomics, transcriptomics, proteomics and metabolomics in the development of personalized treatment strategies would be also highlighted as a key area of research.

Furthermore, the special issue addresses the challenges and opportunities associated with immunotherapy, including the management of immune-related adverse events, mechanisms of resistance, strategies for overcoming immunosuppression within the tumor microenvironment, and potency assessment of therapeutic approaches.

Dr. Satoko Matsueda
Dr. Yoshimi Arima
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

immunotherapy
personalized medicine
pharmacology study
toxicology study
immune-related adverse events
tumor microenvironment
immune escape
neoantigens
immune profiling
potency assessment
biomarker
combination therapy
tumor biology
molecular biology
molecular pathology

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

12 pages, 273 KiB

Open AccessArticle

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series

and

Biomedicines 2023, 11(11), 2974; https://doi.org/10.3390/biomedicines11112974 - 04 Nov 2023

Viewed by 392

Abstract

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) have revolutionized the management of many types of solid tumors, including metastatic renal cell carcinoma (mRCC). Both sequential and combinatorial therapeutic strategies utilizing anti-PD-1 monoclonal antibodies (mAbs) and anti-angiogenic tyrosine kinase inhibitors (TKIs) have demonstrated to improve the survival of patients with mRCC as compared to standard therapies. On the other hand, both ICIs and TKIs are well known to potentially cause thyroid disorder adverse events (TDAEs). However, in the context of sequential therapeutic strategy, it is not clear whether prior anti-angiogenic TKI may increase the risk and/or the severity of ICI-related TDAEs. In this work, by describing and analyzing a case series of mRCC patients treated sequentially with prior TKIs and then with ICIs, we investigated the role of prior anti-angiogenic TKI-based treatment as a potential predisposing factor to anti-PD-1-mediated recurrent TDAEs, as well as its potential impact on the clinical characteristics of nivolumab-mediated recurrent TDAEs. Fifty mRCC patients were included in the analysis. TKI-mediated TDAEs were reported in ten out of fifty patients. TKI-mediated TDAEs were characterized by hypothyroidism in all ten patients. Specifically, 40%, 40% and 20% of patients presented grade 1, 2 and 3 hypothyroidisms, respectively. Following tumor progression and during anti-PD-1 nivolumab treatment, five out of ten patients developed anti-PD-1 nivolumab-mediated recurrent TDAEs. Anti-PD-1 nivolumab-mediated recurrent TDAEs were characterized by an early transient phase of thyrotoxicosis and a late phase of hypothyroidism in all five patients. The TDAEs were grade 1 and 2 in four and one patients, respectively. Prior anti-angiogenic TKI did not modify the clinical characteristics of nivolumab-mediated recurrent TDAEs. However, all five patients required an increased dosage of levothyroxine replacement therapy. In conclusion, our work suggests that prior anti-angiogenic TKI-based treatment significantly increases the risk of ICI-mediated recurrent TDAEs in patients with mRCC without modifying their clinical characteristics. The most relevant effect for these patients is the need to increase the dosage of lifelong levothyroxine replacement therapy. Full article

(This article belongs to the Special Issue Recent Advances in Immunotherapy for Solid Tumors)

11 pages, 246 KiB

Open AccessArticle

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer

Mohammad Sheikh Ahmad

Ashraf Abu Jama

Ahron Yehonatan Cohen

and

Abed Agbarya

Biomedicines 2023, 11(9), 2438; https://doi.org/10.3390/biomedicines11092438 - 31 Aug 2023

Cited by 2 | Viewed by 849

Abstract

Immune checkpoint inhibitors have become the standard of care in the treatment of metastatic non-small-cell lung cancer (NSCLC). The combination of nivolumab plus ipilimumab and chemotherapy has been shown to improve outcomes in terms of overall survival (OS) and progression-free survival (PFS). The aim of this study was to evaluate the outcomes of metastatic NSCLC treated in routine practice on the treatment regimen of the CheckMate 9LA protocol. Medical records of 58 patients treated at Soroka and Bnai Zion Medical Centers between May 2020 and February 2022 were analyzed. All patients were treated with a regimen of platinum-based chemotherapy combined with immunotherapy of nivolumab every three weeks and ipilimumab every 6 weeks. The patients received 2–3 cycles of chemotherapy according to the physician’s choice: platinum-based cisplatin or carboplatin with either pemetrexed or paclitaxel. The median PFS was 10.2 months, longer than that of the 9LA trial (6.7 months). Adenocarcinoma patients exhibited a higher median OS of 13.7 (range 5–33) months than squamous cell carcinoma (SCC) patients at 12.3 (5–20) months and PFS of 10.3 (4–33) months, while squamous cell carcinoma patients had a PFS of 9.2 (4–18) months. Patients whose programmed death ligand-1 (PD-L1) tumor expression level was ≥1% showed a higher median OS than those with PD-L1 expression of less than 1%. Treatment-related adverse events (TRAEs) were reported in 93.1% of patients, mostly grade 1 in severity. The first-line treatment of metastatic NSCLC patients in combination with nivolumab plus ipilimumab and chemotherapy can be given safely in routine clinical practice, with results comparable to those achieved in clinical trials of the regimen. Full article

(This article belongs to the Special Issue Recent Advances in Immunotherapy for Solid Tumors)

Show export options Show export options

Select all

Export citation of selected articles as:

Displaying articles 1-2

Journal Menu

Journal Browser

Special Issue "Recent Advances in Immunotherapy for Solid Tumors"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI